Eupraxia Pharmaceuticals (EPRX) confirms mailing of proxy materials to holders

Rhea-AI Filing Summary

Eupraxia Pharmaceuticals Inc. submitted a Form 6-K as a foreign private issuer to confirm an administrative step related to its upcoming shareholder matters. The company’s transfer agent, TSX Trust Company, states that proxy-related materials were mailed on May 27, 2026 to Registered Securityholders and ESP Holders. This filing simply documents that the required proxy documents have been distributed.

Key Terms

Form 6-K, foreign private issuer, proxy-related materials, Registered Securityholders, +1 more

5 terms

Form 6-K regulatory

"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

proxy-related materials financial

"confirm that copies of the following proxy-related materials were mailed"

Proxy-related materials are the voting documents and information packet shareholders receive ahead of a company meeting, including proposals to elect directors, approve deals, set executive pay, or change rules. Think of them as a ballot and explanatory brochure for a neighborhood association: they explain what’s on the agenda, recommend how to vote, and provide background so investors can decide how governance choices might affect the company’s direction and value.

Registered Securityholders financial

"were mailed on May 27, 2026 to the Registered Securityholders"

ESP Holders financial

"were mailed on May 27, 2026 to the Registered Securityholders and to the ESP Holders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-41923

EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s name)

2198 Yukon Street

Vancouver, British Columbia, Canada V5Y 3P1

Telephone: (250) 590-3968
(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐      Form 40-F ☒

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit
99.1		Confirmation of proxy-related materials mailing

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	EUPRAXIA PHARMACEUTICALS INC.
Date: May 28, 2026	By:	/s/ Alex Rothwell
		Name: Alex Rothwell
		Title: Chief Financial Officer

Exhibit 99.1

TSX TRUST COMPANY

VIA ELECTRONIC TRANSMISSION

May 28, 2026

TO ALL APPLICABLE EXCHANGES AND COMMISSIONS:

RE: EUPRAXIA PHARMACEUTICALS INC.

We are pleased to confirm that copies of the following proxy-related materials were mailed on May 27, 2026 to the Registered Securityholders and to the ESP Holders:

1 Proxy with Request for Financial Statements - Registered Securityholders

2 Voting Instruction Form - ESP Holders

3 Notice of Meeting Combined with Information Circular (Including Virtual Meeting Guide)

4 Proxy Return Envelope

Yours truly,

TSX Trust Company

VANCOUVER 2310 - 733 Seymour Street, Vancouver, BC V6B 0S6     T 604 689-3334 CALGARY 300-5th Avenue SW, 10th floor Calgary, AB T2P 3C4     T 403 218-2800 TORONTO 301 - 100 Adelaide Street West Toronto ON M5H 4H1   Toll Free 1-866-600-5869 T 416 361-0930 MONTRÉAL 1800 - 1190, avenue des Canadiens-de-Montréal, C. P. 37 Montréal (Québec) H3B 0G7   T 514 395-5964

FAQ

What does Eupraxia Pharmaceuticals (EPRX) disclose in this Form 6-K?

Eupraxia Pharmaceuticals discloses that it has filed a Form 6-K as a foreign private issuer to confirm mailing of proxy-related materials. The filing is administrative and records that required shareholder documents have been distributed ahead of a proxy process.

Which proxy materials did Eupraxia Pharmaceuticals (EPRX) confirm mailing?

The company confirms that copies of its proxy-related materials were mailed. While the specific documents are not itemized here, they are described collectively as proxy-related materials intended for shareholders in connection with an upcoming proxy process or meeting.

When were Eupraxia Pharmaceuticals (EPRX) proxy materials mailed to holders?

TSX Trust Company confirms that proxy-related materials were mailed on May 27, 2026. This mailing date applies to both Registered Securityholders and ESP Holders and serves as formal evidence that the documents were sent in advance of proxy-related activities.

Who received Eupraxia Pharmaceuticals (EPRX) proxy-related materials?

Proxy-related materials were mailed to Registered Securityholders and to ESP Holders. This indicates that both common registered shareholders and participants in an ESP program received the necessary documents for participating in upcoming proxy or voting-related actions.

Who handled the mailing of EPRX proxy materials and how was it confirmed?

TSX Trust Company handled the mailing of the proxy-related materials and confirmed this by letter dated May 28, 2026. The letter, filed as Exhibit 99.1, states that the materials were mailed electronically recorded to applicable exchanges and commissions.

Does this Eupraxia Pharmaceuticals (EPRX) filing include financial or earnings data?

This filing does not provide financial or earnings data. It is an administrative confirmation that proxy-related materials were mailed to the appropriate securityholders, serving mainly as a compliance and disclosure record rather than a financial update.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 8.3 KB